4 completed, 3 terminated, 1 recruiting, 1 unknown. 6 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 6 | Terminated 3, Completed 2, Recruiting 1 |
Follow silmitasertib: new trials by email Literature Review of silmitasertib trials Research Report on silmitasertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors Silmitasertib, Irinotecan, Temozolomide - Neuroblastoma, Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | Milton S. Hershey Medical Center | 104 | 2024-10-30 | 2026-10-06 |
| CX-4945 in Viral Community Acquired Pneumonia CX-4945 (SARS-CoV-2 domain), Placebo (SARS-CoV-2 domain), CX-4945 (Influenza virus domain) - Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia | Phase 2 | Terminated | Senhwa Biosciences, Inc. | 45 | 2024-03-20 | 2026-01-08 |
| A Study of Silmitasertib (CX-4945) in Healthy Subject CX-4945 - COVID-19 | Phase 1 | Completed | Senhwa Biosciences, Inc. | 30 | 2022-11-28 | 2025-01-27 |
| Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19) Silmitasertib - Coronavirus | Phase 2 | Terminated | University of Arizona | 31 | 2021-01-21 | 2023-11-07 |
| Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 Silmitasertib, SOC - Covid19 | Phase 2 | Completed | Senhwa Biosciences, Inc. | 20 | 2020-11-30 | 2025-01-16 |
| Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery CX 4945 - Medulloblastoma, Childhood, Medulloblastoma Recurrent | Phase 1 / Phase 2 | Terminated | Pediatric Brain Tumor Consortium | 21 | 2019-07-25 | 2026-10-19 |
| Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) CX-4945 - Carcinoma, Basal Cell | Phase 1 | Completed | Senhwa Biosciences, Inc. | 25 | 2019-04-16 | 2025-05-20 |
| Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma CX-4945, Cisplatin, Gemcitabine - Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | Senhwa Biosciences, Inc. | 127 | 2014-06-01 | 2021-10-22 |
| Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma CX-4945 - Multiple Myeloma | Phase 1 | Unknown | Cylene Pharmaceuticals | 22 | 2010-09-01 | 2011-06-15 |
COVID-19 (4) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoma, Basal Cell (1) · Cholangiocarcinoma (1) · Community-Acquired Pneumonia (1) · Coronavirus Infections (1) · Influenza, Human (1) · Liposarcoma (1) · Medulloblastoma (1) · Microphthalmia, Isolated, with Coloboma 5 (1) · Multiple Myeloma (1) · Neuroblastoma (1) · Osteosarcoma (1) · Plasmacytoma (1)
Senhwa Biosciences, Inc. (5) · Cylene Pharmaceuticals (1) · Milton S. Hershey Medical Center (1) · Pediatric Brain Tumor Consortium (1) · University of Arizona (1)
United States (7) · Taiwan (3) · Canada (1) · South Korea (1)
Chandrika Behura, MD (1) · Chris P. Recknor, MD (1) · Jason Huang, M.D. (1) · Jason Huang, MD (1) · Jin-Ding Huang, PhD (1) · Mitesh Borad, M.D. (1) · Ralph Salloum, MD (1)
UM1CA081457 (1)